Navigation Links
Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
Date:12/10/2012

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Aequus BioPharma, a majority owned subsidiary of Cell Therapeutics, Inc., announced today that Ronald J. Berenson, M.D. was appointed President and CEO of Aequus. In his new position, Dr. Berenson will expand business and product development opportunities for Aequus' GlycoPolymer technology. Aequus is currently developing its GlycoPolymer technology aimed at creating novel biopharmaceuticals with improved pharmacokinetic properties that require less frequent injections than current therapies.

Dr. Berenson has more than 20 years of senior management experience in biotechnology, and was most recently an Entrepreneur in Residence at the University of Washington. He previously co-founded and served as President and CEO of HemaQuest Pharmaceuticals during the company's first three years, successfully ushering the company's programs into early clinical development of its lead compounds. His background also includes senior executive roles at numerous oncology-focused biotechnology companies, including Founder, Director, President and CEO of Xcyte Therapies, Inc. (which merged with Cyclacel), and Founder, Director, Executive Vice President, Chief Medical Officer and Chief Scientific Officer for CellPro, Inc. (CellPro). At CellPro, he was responsible for regulatory submissions that resulted in the U.S. Food and Drug Administration's (FDA) approval of CellPro's lead product, which was the first FDA-approved biological product in cell therapy. Since 2001, he has been on the Board of Ambassadors of the Fred Hutchinson Cancer Center. Dr. Berenson also has contributed to over 90 publications and holds 10 US patents. He completed his oncology training at Stanford University Medical Center, M.D. from Yale Medical School and obtained his B.S. from Stanford University.

"There are more than 100 therapeutic proteins on the market, and they represent one of the fastest growing classes of drugs today. Patient convenience and co
'/>"/>

SOURCE Aequus BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
2. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
3. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
6. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. S1 Biopharma Expands Focus to Include Male Sexual Health
9. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
10. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ... partner and managing director of Warburg Pincus LLC, to the ... to welcome Fred Hassan and the deep, global ... Board," said Robert A. Bradway , chairman and chief ... to innovation will serve Amgen well." Mr. Hassan ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Aug. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... submitted to the FDA a pre-IDE (Investigational Device,Exemption) ... assay,for detection of early lung cancer in veterans. ... million over two years towards the,study that will ...
... Rx, a specialty,pharmaceutical company leveraging its proprietary ... products, today announced the,completion of pilot product ... oxalate, a selective serotonin reuptake inhibitor.,Escitalopram oxalate ... and is marketed under the brand name ...
Cached Medicine Technology:FDA Reviewing Biomoda Submission for Cancer Screening Study 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 3
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... players to know in predictive health analytics , Jvion continues to disrupt ... firm creates predictive software that targets patient and population level illness to drive ...
(Date:7/31/2015)... Memphis, Tenn. (PRWEB) , ... July 31, 2015 , ... ... at Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to ... partnership focused on cancer research between Methodist Healthcare, The West Clinic and The University ...
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... Oct. 17 40|86 Strategic Income,Fund (NYSE: CFD ... 9, 2007 to holders of record at the close ... Fund is a closed-end investment management,company. The Fund,s primary ... in the Fund,s prospectus, the Fund intends to,distribute substantially ...
... Symmetry Medical Inc.,(NYSE: SMA ), an independent ... and other medical markets, announced today the appointment,of ... November 1,2007. Mr. Hynes will assume responsibility ... Europe including the UK, Ireland,France and Switzerland. He ...
... (Oct. 17, 2007) -- Two reports from physician-scientists at ... male infertility. A first report shows that a common ... in the scrotum -- also results in a depletion ... that once a common, simple surgery is used to ...
... cancer screening practices, , , WEDNESDAY, Oct. 17 (HealthDay News) -- ... most cervical cancers -- was far better than the standard ... What,s unclear, however, is whether or not the HPV test ... have a slightly higher false positive rate, and it,s not ...
... in men, it could lead to new treatments, study says, ... a gene that,s essential for the formation of functioning sperm ... from being able to penetrate an egg. , The finding, ... Hill, was based on research with mice. But it might ...
... Oct. 17 Good oral health and good ... 15-19) is a great,opportunity to ensure that children ... the nation,s premier, independent oral health advocacy,organization is ... to promote healthy school lunches. Children who learn,good ...
Cached Medicine News:Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:The latest about male infertility and testosterone from NewYork-Presbyterian/Weill Cornell 2Health News:HPV Test Bests Pap Smear in Studies 2Health News:HPV Test Bests Pap Smear in Studies 3Health News:Gene Mutation Key to Infertility in Male Mice 2Health News:Oral Health America Celebrates National School Lunch Week 2
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator, blunt tip, formed 10.0mm from end. Fits 0.20mm diameter holes & larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge indicating positio...
BD Visitec IOL Manipulator (Lester), 0.25 mm diameter tip angled 45 in, 10 mm from end (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles hand ridge indicating position o...
Lewicky lens manipulator. Also available in titanium....
Medicine Products: